The thalidomide tragedy is now, and always will be, part of Grünenthal's company history. Grünenthal and its family shareholders greatly regret the consequences of the thalidomide tragedy. It is a matter of moral importance to Grünenthal to be actively involved in charitable efforts to improve the situation of thalidomide-affected people on a sustainable basis. We seek to work together with those affected by thalidomide to devise projects for the provision of specific needs-based support.
We have recorded numerous media reports about the intent of the German Contergan Foundation to cease payments to people affected by "Sedalis". Grünenthal's position on this matter is as follows:
At the request of of those affected the Australian Community Affairs Committee last year agreed to convene a hearing into “Support for Australia’s thalidomide survivors”. In several countries, such as Germany and Ireland, Grünenthal marketed its thalidomide products under its own name and brand either directly or through independent companies operating as Grünenthal's direct distributor.
After more than 60 years, researchers at the renowned Dana-Faber Cancer Institute in Boston have succeeded in identifying the causes of thalidomide-induced malformations.
The pensions paid by the Contergan Foundation to people affected by thalidomide in Germany and abroad will be increased by 3.22 percent as of July 1, 2018.
Thalidomide tragedy is surrounded by questions. Misinterpretations follow details about the development of the drug.
Fifty years ago, on May 27, 1968, the so-called "Contergan trial" began before the Grand Criminal Court of the Regional Court of Aachen.